After an initial mistake, it was clarified that the individual who collapsed in the Oval Office was not Novo Nordisk executive Gordon Finlay as previously stated. The true identity of the person who fainted remains unknown, and we regret the error.
During a press conference today, a pharmaceutical executive collapsed unexpectedly while standing behind the US president in the Oval Office. The incident occurred as the Trump administration was unveiling a new agreement for weight-loss medications, causing the man’s knees to give out suddenly.
Upon witnessing the collapse, administration officials and representatives from pharmaceutical companies rushed to assist the individual before he hit the ground. White House Press Secretary Karoline Leavitt explained that during the ‘Most Favored Nations Oval Office Announcement’, a representative from one of the companies fainted. Medical personnel on-site promptly attended to the individual, confirming his well-being. Leavitt assured that the press conference would resume shortly.
The official statement released stated: “During the Most Favored Nations Oval Office Announcement, a representative from one of the companies fainted. The White House Medical Unit responded promptly, and the individual is in good condition. The Press Conference will continue shortly.”
As reporters were escorted out of the Oval Office, cabinet members tended to the collapsed individual by elevating his legs. The cause of the fainting incident remains unknown at this time.
The press conference witnessed executives from pharmaceutical giants Novo Nordisk and Eli Lilly joining forces with the Trump administration to introduce a groundbreaking deal that could have significant implications for the healthcare sector. Under the agreement, the manufacturers of Ozempic, Wegovy, and Zepbound will offer their treatments directly to the public through TrumpRx, a forthcoming government website.
Patients are expected to benefit greatly from this initiative, with the companies anticipating that an oral version of the medications could be priced at $149 (£113) per month pending FDA approval. Additionally, individuals covered under Medicare or Medicaid with approved conditions such as diabetes will see a reduction in the price of injectable versions to $245 (£186) per month.
Receive email updates on the latest news stories of the day.